Landscape Capital Management’s Ionis Pharmaceuticals IONS Stock Holding History

Landscape Capital Management’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-20,146	Closed	-$1.51M	–	768
2026 Q1	$1.51M	Sell	20,146 -4,009	-17%	-$316K	0.1%	308
2025 Q4	$1.91M	Sell	24,155 -2,407	-9%	-$181K	0.13%	242
2025 Q3	$1.74M	Buy	+26,562	New	+$1.3M	0.11%	267
2025 Q1	–	Sell	-10,270	Closed	-$359K	–	749
2024 Q4	$359K	Sell	10,270 -15,165	-60%	-$567K	0.04%	476
2024 Q3	$1.02M	Buy	+25,435	New	+$1.18M	0.1%	260
2019 Q3	–	Sell	-13,605	Closed	-$874K	–	729
2019 Q2	$874K	Hold	13,605	–	–	0.07%	305
2019 Q1	$1.1M	Sell	13,605 -716	-5%	-$46.2K	0.1%	228
2018 Q4	$774K	Buy	+14,321	New	+$730K	0.06%	327
2018 Q3	–	Sell	-7,154	Closed	-$298K	–	744
2018 Q2	$298K	Buy	+7,154	New	+$317K	0.02%	391

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Landscape Capital Management's IONS Position: Q2 2026 in Review

Landscape Capital Management sold out of Ionis Pharmaceuticals (IONS) in Q2 2026, closing a stake of 20,146 shares — an estimated $1.51M sold.

Landscape Capital Management first reported a position in IONS in Q2 2018 and held it in 9 quarters. The position peaked at $1.91M in Q4 2025. 514 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

Landscape Capital Management reported no remaining Ionis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Landscape Capital Management sold 20,146 Ionis Pharmaceuticals shares in Q2 2026, an estimated $1.51M.
Landscape Capital Management first reported a position in Ionis Pharmaceuticals in Q2 2018 and held it in 9 quarters.
Landscape Capital Management's Ionis Pharmaceuticals position peaked at $1.91M in Q4 2025.
514 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on Landscape Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.